Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Details 1)

v2.4.1.9
Fair Value Measurements (Details 1) (USD $)
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Balance, beginning   $ 23us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
Change in fair value of Teva option   (23)us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
Estimated fair value of warrants assumed in merger on January 2, 2014   10,475us-gaap_FairValueAdjustmentOfWarrants
Estimated fair value of warrants issued in January 2014 common stock sale   3,696COCP_EstimatedFairValueOfWarrants
Estimated fair value of warrants exchanged for common shares 9,426,000COCP_EstimatedFairValueOfWarrantsExchangedForCommonShares   
Change in fair value of warrants for the year ended December 31, 2014   (2,082)COCP_ChangeInFairValueOfWarrants
Balance, ending   12,089us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
Unobservable Inputs (Level 3) [Member]    
Balance, beginning 8,464us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel3Member
 
Change in fair value of Teva option     
Estimated fair value of warrants assumed in merger on January 2, 2014     
Estimated fair value of warrants issued in January 2014 common stock sale     
Estimated fair value of warrants exchanged for common shares (9,426)COCP_EstimatedFairValueOfWarrantsExchangedForCommonShares
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel3Member
 
Change in fair value of warrants for the year ended December 31, 2014 (14,418)COCP_ChangeInFairValueOfWarrants
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel3Member
 
Balance, ending $ 13,456us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
/ us-gaap_FairValueByFairValueHierarchyLevelAxis
= us-gaap_FairValueInputsLevel3Member